Lifesaving Vaccine Technology Act of 1999

referredUnited States· United States Congress· EN

Introduced

24 March 1999

Last action

6 April 1999 · Referred

Status

Referred to the Subcommittee on Health and Environment, for a period to be subsequently determined by the Chairman.

Summary

Lifesaving Vaccine Technology Act of 1999 - Amends the Internal Revenue Code to establish an income tax credit for 30 percent of the qualified expenses (excluding amounts funded by any grant, contract, or otherwise by another person or any governmental entity) for medical research related to developing vaccines against widespread diseases like malaria, tuberculosis, HIV, or any infectious disease (of a single etiology) which, according to the World Health Organization, causes over one million human deaths annually. States that any qualified vaccine research expenses for a taxable year to which an election under this Act applies shall not be taken into account for purposes of determining the credit allowable for increasing research expenditures. Denies such a credit with respect to any vaccine research (other than human clinical testing) conducted outside the United States. States that the vaccine research credit shall include an amount equal to 20 percent of the amount paid by the taxpayer to acquire qualified research stock in a corporation if the corporation waives its own right to the credit and meets other specified criteria. Declares that it is the sense of Congress that if the vaccine research credit is allowed to any corporation or shareholder of a corporation, the corporation should certify to the Secretary of the Treasury that, within one year after that vaccine is first licensed, the corporation will establish a good faith plan utilizing technology transfer, differential pricing, in-country production, or other mechanisms to maximize international access to high quality and affordable vaccines. Directs the Institute of Medicine to study and report to Congress on the effectiveness of the vaccine research credit in stimulating vaccine research. Expresses the sense of Congress that the President and Federal agencies (including the Departments of State, Health and Human Services, and the Treasury) should work together in vigorous support of the creation and funding of a multi-lateral, international effort, such as a vaccine purchase fund, to accelerate the introduction of vaccines to which the vaccine research credit applies and of other priority vaccines into the poorest countries in the world. Expresses the sense of Congress that flexible or differential pricing for vaccines, providing lowered prices for the poorest countries, is one of several valid strategies to accelerate the introduction of vaccines in developing countries.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

24 March 1999
Introduced
Referred to the Committee on Ways and Means, and in addition to the Committee on Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Source: IntroReferral
24 March 1999
Introduced
Referred to the Committee on Ways and Means, and in addition to the Committee on Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Source: IntroReferral
24 March 1999
Introduced
Introduced in House
Source: IntroReferral
24 March 1999
Introduced
Introduced in House
Source: IntroReferral
6 April 1999
Referred
Referred to the Subcommittee on Health and Environment, for a period to be subsequently determined by the Chairman.
Source: Committee

Votes

No vote records are attached yet.

Versions

Introduced in House · 24 March 1999 · Download file

Documents

3 official files

Introduced in House (text)

View file Download file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Vertaal naar

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Introduced in House (text)
Introduced in House · EN · 24 March 1999
View Download Open at official source
Introduced in House (PDF)
Introduced in House · EN · 24 March 1999
View Download Open at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Vertaal naar
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House
summary · EN · 24 March 1999
Open at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Vertaal naar
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.

Official source: https://www.congress.gov/bill/106th-congress/house-bill/1274
Open data entity: https://api.congress.gov/v3/bill/106/hr/1274
us · 106-hr-1274 · source updated 3 June 2026